<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778750</url>
  </required_header>
  <id_info>
    <org_study_id>14-01692</org_study_id>
    <nct_id>NCT02778750</nct_id>
  </id_info>
  <brief_title>Evaluation Of The Pan-microbiome and Host Immune Response in CF</brief_title>
  <official_title>Evaluation Of The Pan-microbiome and Host Immune Response in Cystic Fibrosis (CF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will examine temporal and regional dynamic changes in the microbiome of Cystic&#xD;
      Fibrosis patients to explore microbiome features that are associated with an inflammatory&#xD;
      phenotype. Investigators hypothesize that temporal and spatial differences in lung microbiome&#xD;
      are associated with host inflammatory responses.&#xD;
&#xD;
      While chronic and polymicrobial airway colonization are commonly recognized in cystic&#xD;
      fibrosis (CF), it is unclear what factors of the microbial environment lead to infection with&#xD;
      pathogenic microorganism. This is a multi center, longitudinal cohort of adult Cystic&#xD;
      Fibrosis subjects recruit4ed from NYU and Columbia to understand how changes in the airway&#xD;
      microbiome may affect the host inflammatory responses in Cystic Fibrosis (CF). There will be&#xD;
      three approaches to understanding inflammatory responses; 1) a longitudinal assessment of&#xD;
      temporal changes in the microbiome over a 6-month period of clinical stability; 2) comparison&#xD;
      of the regional differences in airway microbiome between lung segments with more versus less&#xD;
      disease; 3) evaluation of functional aspects of the lung microbiome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Oral Inflammatory markers</measure>
    <time_frame>Baseline, 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Sputum Inflammatory Markers measured using research bronchoscopy</measure>
    <time_frame>Baseline, 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Gut Microbiome</measure>
    <time_frame>Baseline, 6 Months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cystic Fibrosis (CF)</condition>
  <arm_group>
    <arm_group_label>Stable Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapid Decliner Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Two-Bronchoscope Technique</intervention_name>
    <description>Used to validate the use of sputum to sample the lower airway microbiome</description>
    <arm_group_label>Rapid Decliner Group</arm_group_label>
    <arm_group_label>Stable Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Multicenter study to create a longitudinal cohort of adult CF subjects recruited from NYU&#xD;
        and Columbia. A subgroup of subjects will be selected for a more invasive assessment of the&#xD;
        lung microbiome with research bronchoscopy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CF diagnosis&#xD;
&#xD;
          -  able to produce sputum&#xD;
&#xD;
          -  no recent (one month) exacerbation defined as physician treatment with antibiotics for&#xD;
             ≥ 7days&#xD;
&#xD;
          -  FEV1 ≥ 30% of predicted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Initiation of any new chronic therapy (e.g., ibuprofen, aerosolized rhDNase,&#xD;
             hypertonic saline, azithromycin, tobramycin inhalation solution, aztreonam inhalation&#xD;
             solution, ivacaftor) within 8 weeks prior to enrolment&#xD;
&#xD;
          -  introduction of vitamins or proton pump inhibitors within 8 weeks prior to enrolment&#xD;
&#xD;
          -  use of new investigational therapy within 4 weeks&#xD;
&#xD;
          -  current smoker; use of oral corticosteroids&#xD;
&#xD;
          -  Initiation of treatment or change in regimen for allergic bronchopulmonary&#xD;
             aspergillosis or nontuberculous mycobacteria within 8 weeks.&#xD;
&#xD;
          -  liver enzymes &gt; 3 times the upper limit&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
        Additional Exclusion Criteria for Bronchoscopy Subgroup (Aims 2 and 3):&#xD;
&#xD;
          -  FEV1 &lt; 50% of predicted.&#xD;
&#xD;
          -  Significant cardiovascular disease defined as abnormal EKG, known or suspected&#xD;
             coronary artery disease or congestive heart failure.&#xD;
&#xD;
          -  Significant renal disease (Creatinine Clearance &lt; 30%).&#xD;
&#xD;
          -  Severe malnutrition (BMI &lt;18kg/m2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo Segal</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis (CF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

